The stay significantly defers litigation risk and potential cash drain for Cellectis, shifting the primary venue to the PTAB where Cellectis has a procedural advantage as Senior Party. Monitor PTAB Interference No. 106,318 motions phase outcome — if Factor Bioscience loses its motions, the stay becomes indefinite, effectively removing the infringement overhang for CLLS shares.
Price Chart
Executive Summary
The District of Delaware granted-in-part Cellectis's motion to stay the patent infringement action brought by Factor Bioscience pending the outcome of PTAB Interference No. 106,318. Cellectis was designated the 'Senior Party' in the interference, and a finding in its favor could cancel all of Factor Bioscience's patent claims, eliminating the litigation risk. The stay runs at least through the PTAB motions phase; if Factor Bioscience does not prevail there, the stay continues to final resolution.
Court Ruling Details
Key Facts
- Cellectis was granted a stay of the patent infringement action pending PTAB Interference No. 106,318, with Cellectis designated as Senior Party.
- The stay runs at least through the PTAB motions phase; if Factor Bioscience does not prevail on its motions, the stay continues until final resolution of the interference.
- All claims of the Asserted Patents (U.S. Patent Nos. 10,662,410, 10,829,738, and 10,982,229) are at issue in the interference.
- Cellectis has no commercial products on the market at this time, and the court found no undue prejudice from the stay.
- Approximately 75% of senior parties prevail in interferences, per Cellectis's cited data.
- No damages were awarded; no injunction was issued.
Financial Impact
No financial figures were stated in the ruling.
Risk Factors
- If Factor Bioscience prevails during the motions phase, the stay may be lifted and the district court case resumes.
- The interference could last two years or more, creating prolonged uncertainty on patent validity even if the stay remains in place.
- AstraZeneca Ireland Limited remains a co-defendant; a loss at the PTAB could revive infringement allegations against AZN as well.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-22lm59hl-CLLS |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $1.02 (+44.30%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $1.02 (−44.30%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $1.02 (−64.05%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $1.02 (−66.02%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $1.02 (−63.98%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $1.02 (−63.98%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $1.02 (−67.01%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $1.02 (−67.95%) |
May 12, 2026 24w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $1.02 (−74.26%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $1.02 (−72.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers